Frontiers in Endocrinology,
Journal Year:
2023,
Volume and Issue:
14
Published: Nov. 13, 2023
Background
Metastatic
prostate
cancer
(PCa)
poses
a
significant
public
health
concern.
While
radiation
therapy
(RT)
is
commonly
utilized
in
the
treatment
of
synchronous
oligometastatic
hormone
sensitive
(OM-HSPC),
occurrence
biochemical
recurrence
still
remains.
To
deepen
our
understanding
and
optimize
outcome
OM-HSPC,
we
conducted
this
study
to
investigate
characteristics
PCa
progression
explore
potential
synergistic
mechanisms
involving
carbon-ion
radiotherapy
(CIRT)
neoadjuvant
androgen
deprivation
(naADT)
OM-HSPC.
Methods
Metabolomic
analysis
was
with
72
urinary
samples
(at
different
timepoints)
from
33
Patients
(T2-3N0M0-1b)
18
healthy
volunteers
by
using
liquid
chromatography-tandem
mass
spectrometry
(LC-MS/MS).
MetaboAnalyst
website
R
software
were
employed
for
metabolomic
visualization
(using
criteria
p
value
<
0.05
|FC|>1.5).
The
impact
CIRT
on
metabolism
further
verified
explored
through
vitro
vivo
experiments.
Results
We
found
that
most
metabolites
(223
out
233)
upregulated
treatment-naïve
compared
samples.
After
naADT,
60
core
risk
significantly
related
PCa’s
progression,
glutamine
level
which
higher
OM-HSPC
other
groups.
Remarkably,
after
treatment,
levels
reduced
Experiments
confirmed
CIRT’s
ability
suppress
tumors
its
enhancement
intervention.
Conclusion
naADT
might
synergistically
inhibit
HS-OMPC
development,
even
ADT
resistance
repression,
moreover,
be
novel
target
improved
efficacy
CIRT.
PLoS ONE,
Journal Year:
2024,
Volume and Issue:
19(6), P. e0304941 - e0304941
Published: June 12, 2024
The
recent
usage
of
immunotherapy
combined
with
chemoradiotherapy
has
improved
survival
in
advanced
non-small
cell
lung
cancer
(NSCLC)
patients.
However,
determining
the
most
effective
therapy
combination
remains
a
topic
debate.
Research
suggests
immune
checkpoint
inhibitors
(ICIs)
post-chemoradiotherapy
enhance
survival,
but
impact
concurrent
ICIs
during
on
rapid
disease
progression
is
unclear.
This
meta-analysis
aims
to
assess
effectiveness
and
safety
radiotherapy
or
cancer.
Journal of Cancer,
Journal Year:
2023,
Volume and Issue:
15(1), P. 275 - 292
Published: Dec. 5, 2023
In
spite
of
numerous
existing
bio-surveillance
systems
for
predicting
glioma
(GBM)
prognosis,
enhancing
the
efficacy
immunotherapy
remains
an
ongoing
conundrum.
The
continual
scrutiny
dynamic
interplay
between
sphingolipid
metabolic
pathway
and
tumor
immunophenotypes
has
unveiled
potential
implications.
However,
intricate
orchestration
functional
regulatory
mechanisms
by
long
non-coding
RNAs
(lncRNAs)
in
GBM,
particularly
context
metabolism,
cryptic.
Aging,
Journal Year:
2024,
Volume and Issue:
unknown
Published: March 5, 2024
Background:
The
quest
for
dependable
biomarkers
to
predict
responses
immune
checkpoint
inhibitors
(ICIs)
combined
with
chemotherapy
in
advanced
non-small
cell
lung
cancer
remains
unfulfilled.
HOXC9,
known
its
role
oncogenesis
and
creating
a
suppressive
tumor
microenvironment
(TME),
shows
promise
enhancing
predictive
precision
when
included
as
TME
biomarker.
This
study
explores
the
significance
of
HOXC9
ICI
plus
efficacy
adenocarcinoma
(LUAD).
Methods:
Following
bioinformatic
findings,
assays
were
performed
ascertain
effects
Hoxc9
on
response
programmed
death
1
(PD-1)
blockade.
Furthermore,
cohort
LUAD
patients
prospectively
enrolled
receive
anti-PD-1
chemotherapy.
Based
expression
levels,
baseline
characteristics,
clinical
outcomes,
potential
PD-L1,
CD4,
CD8,
CD68,
FOXP3
was
integrally
analyzed.
not
only
mediated
oncogenesis,
but
also
corelated
TME.
CMT167
LLC
lines
unveiled
impacts
proliferation,
invasion,
migration.
Subsequently,
tumor-bearing
murine
models
established
validate
inverse
relationship
between
effective
CD8+
T
cells.
Results:
Inhibition
significantly
curtailed
growth
(P<0.05),
independent
PD-1
In
patient
studies,
while
individual
markers
fell
short
prognosticating
survival,
notable
elevation
CD8-positive
observed
responders
(P=0.042).
Yet,
amalgamation
other
provided
more
distinct
differentiation
non-responders.
Notably,
displaying
PD-L1+/HOXC9-
CD8+/HOXC9-
phenotypes
exhibited
prolonged
progression-free
survival.
Conclusions:
may
serve
biomarker
amplifying
ICIs
chemotherapy,
which
is
viable
oncogene
therapeutic
target
immunotherapy
LUAD.
Molecular Pain,
Journal Year:
2024,
Volume and Issue:
20
Published: Jan. 1, 2024
The
interaction
between
the
immune
system
and
brain,
crucial
for
blood–brain
barrier
integrity,
is
a
potential
factor
in
migraine
development.
Although
there’s
evidence
of
connection
dysregulation
migraine,
clear
causal
link
has
been
lacking.
To
bridge
this
knowledge
gap,
we
performed
two-sample
Mendelian
randomization
(MR)
analysis
731
cell
phenotypes
to
determine
their
causality
with
which
parameters
included
fluorescence,
abundance,
count,
morphology.
Sensitivity
pleiotropy
checks
validated
our
findings.
After
applying
false
discovery
rate
correction,
MR
study
identified
35
significant
(
p
<
0.05).
Of
these,
24
showed
protective
effect
(inverse
variance
weighting
:
0.05,
odds
ratio
<1),
11
were
risk
factors
>1).
limited
by
population
sample
size
population-specific
genetic
variations,
uncovers
certain
markers
providing
new
insights
into
disorder’s
pathophysiology.
These
discoveries
are
developing
targeted
biomarkers
personalized
treatments.
research
enhances
understanding
cells’
role
may
substantially
improve
patient
outcomes
lessen
its
socio-economic
impact.
Background:
The
recent
usage
of
immunotherapy
combined
with
chemoradiotherapy
has
improved
survival
in
advanced
non-small
cell
lung
cancer
(NSCLC)
patients.
However,
determining
the
most
effective
therapy
combination
remains
a
topic
debate.
Research
suggests
immune
checkpoint
inhibitors
(ICIs)
post-chemoradiotherapy
enhance
survival,
but
impact
concurrent
ICIs
during
on
rapid
disease
progression
is
unclear.
This
meta-analysis
aims
to
assess
effectiveness
and
safety
radiotherapy
or
cancer.
Methods:
We
searched
PubMed,
Embase,
Cochrane
Library,
Web
Science
for
relevant
studies,
extracting
data
overall
response
rate
(ORR),
progression-free
(PFS),
(OS),
adverse
events
(AEs).
Results:
analysis
included
ten
studies
490
participants.
Stage
III
NSCLC
ORR
was
81.8%,
while
IV
39.9%.
One-year
PFS
OS
were
68.2%
82.6%,
compared
27.9%
72.2%
IV.
Common
anemia
(46.6%),
nausea
(47.6%),
rash
(36.4%),
radiation
pneumonitis
(36.3%).
Conclusions:
Our
shows
are
safe
NSCLC,
particularly
stage
patients
at
risk
before
starting
after
chemoradiotherapy.
findings
support
further
phase
trials.
review
protocol
registered
PROSPERO
(CRD42023493685)
detailed
NIHR
HTA
programme
website.
Clinical & Translational Oncology,
Journal Year:
2023,
Volume and Issue:
26(5), P. 1063 - 1076
Published: Nov. 3, 2023
Abstract
Non-small-cell
lung
cancer
(NSCLC)
has
an
extremely
low
5-year
survival
rate,
with
the
only
effective
treatment
being
immunoradiotherapy
(iRT).
Here,
we
review
progress
of
clinical
research
on
iRT
for
non-small-cell
over
2018–2023,
as
well
future
directions.
We
first
discuss
synergistic
mechanisms
iRT,
reflected
in
three
aspects:
immune
regulation
RT,
RT-activated
immune-related
pathways,
and
RT-related
sensitization.
may
include
either
external-beam
or
stereotactic-body
RT
combined
checkpoint
inhibitors
(e.g.,
immunoglobulins
against
programmed
cell
death
(PD)
1/PD
ligand
1
CD8
+
T
lymphocyte
antigen
4)
traditional
Chinese
medicine
drugs.
Regarding
effectiveness
safety,
increases
overall
progression-free
tumor
control
rate
among
patients
NSCLC
but
without
a
considerable
increase
toxicity
risk.
finally
challenges
directions
reported
2018–2023.
Life,
Journal Year:
2024,
Volume and Issue:
14(12), P. 1608 - 1608
Published: Dec. 4, 2024
Exosome-derived
microRNAs
(miRNAs)
are
potential
biomarkers
for
lung
cancer
detection
and
monitoring
through
liquid
biopsy.
These
small,
non-coding
RNA
molecules
found
within
exosomes,
which
extracellular
vesicles
released
from
cells.
Their
stability
in
biofluids,
such
as
blood,
positions
them
candidates
minimally
invasive
diagnostics.
Multiple
studies
have
shown
that
patients
exhibit
distinct
miRNA
profiles
compared
to
healthy
individuals.
This
finding
suggests
exosome-derived
miRNAs
could
serve
valuable
diagnosis,
prognosis,
evaluating
therapeutic
responses.
review
summarizes
recent
research
on
biopsies,
including
pleural
effusion,
lavage,
cancer,
focusing
publications
the
last
five
years.
Frontiers in Endocrinology,
Journal Year:
2023,
Volume and Issue:
14
Published: Nov. 2, 2023
Background
The
continuous
exploration
of
oligometastatic
disease
has
led
to
the
remarkable
achievements
local
consolidative
therapy
(LCT)
and
favorable
outcomes
for
this
disease.
Thus,
study
investigated
potential
benefits
LCT
in
patients
with
single-organ
metastatic
pancreatic
ductal
adenocarcinoma
(PDAC).
Methods
Patients
PDAC
diagnosed
between
2010
-
2019
were
identified
from
Surveillance,
Epidemiology,
End
Results
(SEER)
database.
Propensity
score
matching
(PSM)
was
performed
minimize
selection
bias.
Factors
affecting
survival
assessed
by
Cox
regression
analysis
Kaplan-Meier
estimates.
A
total
12900
database,
including
635
who
received
chemotherapy
combined
a
1:1
PSM
only
chemotherapy.
combination
demonstrated
extended
median
overall
(OS)
approximately
57%,
more
than
those
underwent
alone
(11
vs.
7
months,
p
<
0.001).
Furthermore,
multivariate
revealed
that
LCT,
younger
age
(<
65
years),
smaller
tumor
size
50
mm),
lung
metastasis
(reference:
liver)
prognostic
factors
PDAC.
Conclusion
OS
cancer
may
be
prolonged
compared
Nevertheless,
additional
prospective
randomized
clinical
trials
are
required
support
these
findings.
Research Square (Research Square),
Journal Year:
2023,
Volume and Issue:
unknown
Published: Dec. 2, 2023
Abstract
Background:
The
administration
of
thoracic
irradiation
has
been
shown
to
extend
the
overall
survival
rate
in
patients
with
stage
IV
non-small
cell
lung
cancer
(NSCLC).
However,
few
studies
have
evaluated
efficacy
and
safety
radiotherapy
combined
immunotherapy
advanced
NSCLC.
Methods:
Data
pertaining
progression-free
(PFS),
(OS),
treatment
response,
adverse
events
62
diagnosed
NSCLC
who
underwent
followed
by
radiation
therapy
(TRT)
were
retrospectively
gathered.
Results:
median
PFS
OS
9
15
months,
respectively.
showed
different
responses,
5
(8.06%)
achieving
complete
response
(CR),
36
(58.06%)
partial
(PR),
19
(30.65%)
showing
stable
disease
(SD),
2
(3.23%)
experiencing
progressive
(PD).
achieved
CR
or
PR
had
longer
than
SD
PD
[median
PFS:
11.00
vs
7.00
HR:
0.45
(0.22-0.91),
P
<0.001;
OS:
not
reached
(NR)
8.00
0.29
(0.13-0.67),
<0.001,
respectively].
Conclusions:
Thoracic
targeting
primary
lesion
following
can
delay
progression
survivalwhile
maintaining
an
acceptable
level
safety.
Frontiers in Endocrinology,
Journal Year:
2023,
Volume and Issue:
14
Published: Nov. 13, 2023
Background
Metastatic
prostate
cancer
(PCa)
poses
a
significant
public
health
concern.
While
radiation
therapy
(RT)
is
commonly
utilized
in
the
treatment
of
synchronous
oligometastatic
hormone
sensitive
(OM-HSPC),
occurrence
biochemical
recurrence
still
remains.
To
deepen
our
understanding
and
optimize
outcome
OM-HSPC,
we
conducted
this
study
to
investigate
characteristics
PCa
progression
explore
potential
synergistic
mechanisms
involving
carbon-ion
radiotherapy
(CIRT)
neoadjuvant
androgen
deprivation
(naADT)
OM-HSPC.
Methods
Metabolomic
analysis
was
with
72
urinary
samples
(at
different
timepoints)
from
33
Patients
(T2-3N0M0-1b)
18
healthy
volunteers
by
using
liquid
chromatography-tandem
mass
spectrometry
(LC-MS/MS).
MetaboAnalyst
website
R
software
were
employed
for
metabolomic
visualization
(using
criteria
p
value
<
0.05
|FC|>1.5).
The
impact
CIRT
on
metabolism
further
verified
explored
through
vitro
vivo
experiments.
Results
We
found
that
most
metabolites
(223
out
233)
upregulated
treatment-naïve
compared
samples.
After
naADT,
60
core
risk
significantly
related
PCa’s
progression,
glutamine
level
which
higher
OM-HSPC
other
groups.
Remarkably,
after
treatment,
levels
reduced
Experiments
confirmed
CIRT’s
ability
suppress
tumors
its
enhancement
intervention.
Conclusion
naADT
might
synergistically
inhibit
HS-OMPC
development,
even
ADT
resistance
repression,
moreover,
be
novel
target
improved
efficacy
CIRT.
